CD137 binding fibronectin type III domains

Patent metadata

Field	Value
Publication number	US-11345739-B2
Application number	US-202016820844-A
Country	US
Kind code	B2
Filing date	Mar 17, 2020
Priority date	Dec 14, 2016
Publication date	May 31, 2022
Grant date	May 31, 2022

Abstract

FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

First claim

What is claimed is:

1. A protein comprising an amino acid sequence that is at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, and 224.

2. The protein of claim 1 , wherein the amino acid sequence is at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, and 224.

3. The protein of claim 1 , wherein the protein has at least one substitution at a residue selected from the group consisting of 11, 14, 17, 37, 46, 73, and 86 corresponding to SEQ ID NO: 4.

4. The protein of claim 1 , wherein the protein is conjugated to a heterologous molecule.

5. The protein of claim 4 , wherein the heterologous molecule is a detectable label, a cytotoxic agent, or both.

6. The protein of claim 5 , wherein the cytotoxic agent is a selected from a chemotherapeutic agent, a drug, a growth inhibitory agent, a toxin, an enzymatically active toxin of bacterial origin or fragments thereof, an enzymatically active toxin of fungal origin or fragments thereof, an enzymatically active toxin of plant origin or fragments thereof, an enzymatically active toxin of animal origin or fragments thereof, or a radioactive isotope.

7. The protein of claim 5 , wherein the cytotoxic agent is selected from daunomycin, doxorubicin, methotrexate, vindesine, diphtheria toxin, ricin, geldanamycin, maytansinoids or calicheamicin.

8. The protein of claim 5 , wherein the cytotoxic agent is selected from diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins, Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, or tricothecenes.

9. The protein of claim 5 , wherein the cytotoxic agent is a radionuclide, selected from 212 Bi, 131 I, 131 In, 90 Y, or 186 Re.

10. The protein of claim 5 , wherein the cytotoxic agent is conjugated to the protein by a linker.

11. The protein of claim 5 , wherein the cytotoxic agent is complexed with a chelating agent.

12. The protein of claim 5 , wherein the detectable label is selected from a radioactive isotope, a magnetic bead, a metallic bead, a colloidal particle, a fluorescent dye, an electron-dense reagent, an enzyme, a biotin, a digoxigenin, a hapten, a luminescent molecule, a chemiluminescent molecule, a fluorochrome, a fluorophore, a fluorescent quenching agent, a colored molecule, a cintillant, an avidin, astreptavidin, a protein A, a protein G, an antibody, an antibody fragment, a polyhistidine, a Ni 2+ , a flag tag, a myc tag, a heavy metal, an alkaline phosphatase, a peroxidase, a luciferase, an electron donor, an electron acceptor, an acridinium ester, or a colorimetric substrate.

13. The protein of claim 5 , wherein the detectable label is auristatin, monomethyl auristatin phenylalanine, dolostatin, chemotherapeutic agent, a drug, a growth inhibitory agent, a toxin, or a radioactive isotope.

14. The protein of claim 5 , wherein the detectable label is conjugated to the protein by a linker.

15. The protein of claim 5 , wherein the detectable label is complexed with a chelating agent.

16. The protein of claim 1 , further comprising a methionine at the N-terminus of the protein.

17. The protein of claim 1 , wherein the protein is coupled to a half-life extending moiety.

18. The protein of claim 17 , wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG), albumin, albumin variant, or at least a portion of an Fc region of an immunoglobulin.

19. A composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.

20. A kit comprising the protein of claim 1 .

Assignees

• Janssen Biotech Inc

Inventors

• Diem Michael
• Hawkins Rebecca
• Jacobs Steven
• Sepulveda Manuel

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/575

  for cancer · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• C07K14/78 Primary

  Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title

• A61P35/00

  Antineoplastic agents · CPC title